Aclaris Therapeutics, Inc.: Innovating Therapies for Immune-Inflammatory Diseases Pennsylvania-based Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies for immune-inflammatory diseases in the United States. The company operates through two segments: Therapeutics and Contract Research. Aclaris' Therapeutics segment is dedicated to identifying and developing novel treatments for significant unmet needs in immuno-inflammatory diseases. Meanwhile, its Contract Research segment offers laboratory services. The company's current drug candidates include Zunsemetinib, a promising MK2 inhibitor in development for the treatment of moderate to severe rheumatoid and Psoriatic arthritis and Hidradenitis suppurativa. It has also developed ATI-1777, a soft JAK 1/3 inhibitor for moderate to severe atopic dermatitis, and ATI-2138, an ITK/TXK/JAK3 inhibitor being studied for its potential to treat T cell-mediated autoimmune diseases. Aclaris Therapeutics has also developed a Gut-Biased Program for inflammatory bowel disease, as well as ATI-2231, an oral MK2 inhibitor currently being evaluated for the treatment of pancreatic and metastatic breast cancer. Founded in 2012, Aclaris Therapeutics is committed to improving patient outcomes by developing highly effective treatments for hard-to-treat immune-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics's ticker is ACRS
The company's shares trade on the NASDAQ stock exchange
They are based in Wayne, Pennsylvania
There are 51-200 employees working at Aclaris Therapeutics
It is aclaristx.com
Aclaris Therapeutics is in the Healthcare sector
Aclaris Therapeutics is in the Biotechnology industry
The following five companies are Aclaris Therapeutics's industry peers: